Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial
- 1 April 2007
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 369 (9569), 1261-1269
- https://doi.org/10.1016/s0140-6736(07)60597-2
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected IndividualsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- Screening and selecting for optimized antiretroviral drugs: rising to the challenge of drug resistanceCurrent Medical Research and Opinion, 2006
- Treatment for Adult HIV InfectionJama-Journal Of The American Medical Association, 2006
- Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trialsThe Lancet, 2006
- Effects of drug resistance on viral load in patients failing antiretroviral therapyJournal of Medical Virology, 2006
- Drug-Class-Wide Resistance to Antiretrovirals in HIV-Infected Patients Failing Therapy: Prevalence, Risk Factors and Virological OutcomeAntiviral Therapy, 2005
- Emerging anti-HIV drugsEmerging Drugs, 2005
- Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and AustraliaThe New England Journal of Medicine, 2003
- Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South AmericaThe New England Journal of Medicine, 2003
- New antiretroviral drugsClinical Microbiology & Infection, 2003